TranScrip Partners Announce U.S. Expansion
Published: Apr 05, 2013
TranScrip Partners supports biopharmaceutical product development and life-cycle management across a client base of over 80 companies. TranScrip Partners challenges the traditional CRO model by offering to clients both top-level therapeutic expertise in overcoming the hurdles encountered from translational medicine to successful registration and market access and the staff to support the projects. Services offered by TranScrip Partners include development and market positioning strategies for early molecules as well as tailored support in drug development, medical affairs, pharmacovigilance, regulatory and medical writing during pre and post-approval.
The unique “one-stop shop”, character of its organisational model, offers an innovative solution to managing the ever increasing costs of fixed overheads in Pharmaceutical R&D.
TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers that do, and doers who think strategically.
Working for more than 80 companies across four continents, TranScrip challenges the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.
Glenn S Tillotson PhD
TranScrip Partners (USA) LLC
2941 Honeymead Road
Downingtown PA 19335
Tel: 610 383 5705 office
Cell: 858 361 3613
TranScrip Partners LLP
400 Thames Valley Park Drive
Thames Valley Park, Reading, United Kingdom
Tel: +44 1189 637846
Fax: +44 1189 637497